Your browser doesn't support javascript.
loading
Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer.
Slagter, Astrid E; Caspers, Irene A; van Grieken, Nicole C T; Walraven, Iris; Lind, Pehr; Meershoek-Klein Kranenbarg, Elma; Grootscholten, Cecile; Nordsmark, Marianne; van Sandick, Johanna W; Sikorska, Karolina; van de Velde, Cornelis J H; Jansen, Edwin P M; Verheij, Marcel; van Laarhoven, Hanneke W M; Cats, Annemieke.
Afiliación
  • Slagter AE; Department of Radiation Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
  • Caspers IA; Department of Gastrointestinal Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
  • van Grieken NCT; Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands.
  • Walraven I; Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands.
  • Lind P; Department of Radiation Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
  • Meershoek-Klein Kranenbarg E; Department of Epidemiology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
  • Grootscholten C; Department of Oncology, Stockholm Söder Hospital, 118 83 Stockholm, Sweden.
  • Nordsmark M; Karolinska Institutet, Research Oncology, 171 77 Stockholm, Sweden.
  • van Sandick JW; Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Sikorska K; Department of Gastrointestinal Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
  • van de Velde CJH; Department of Oncology, Aarhus University, 8000 Aarhus, Denmark.
  • Jansen EPM; Department of Surgery, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
  • Verheij M; Department of Biometrics, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
  • van Laarhoven HWM; Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Cats A; Department of Radiation Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Cancers (Basel) ; 14(12)2022 Jun 15.
Article en En | MEDLINE | ID: mdl-35740628
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos